Skip to main content

Table 1 The discrepant regions associated with human diseases

From: Characterization of large-scale genomic differences in the first complete human genome

Cytobands

CHM13_Position

Hg38_Position

Type

Reported CNV

Genes

Disease

1p13.3

chr1:109711485–109711489

chr1:109682999–109701443

DEL

 

GSTM1

Urinary system disease [32]

1p21.1

chr1:103546781–103735057

chr1:103697900–103697950

INV

 

AMY1A, AMY1B, AMYP1

Neurological disease [33]

1p36.13

chr1:16007445–16027869

chr1:16565700–16565800

INS

 

NBPF1

Neurodevelopmental disorders [34], Cancer

1q21.1-1q21.2

chr1: 143959965–143983984

chr1:146251047–148716074

INV

 

BCL9, NOTCH2NLB, CHD1L, NBPF12, PRKAB2, FMO5, ACP6, GJA8, GPR89B, NBPF11, NBPF14, PPIAL4G,

Neurodevelopmental disorders [13,14,15,16]

1q31.3

chr1:196105143–196105148

chr1:196758727–196843410

DEL

 

CFHR3, CFHR1

Immunological disease [35]

1q32.2

chr1:206810072–206810076

chr1:207542838–207561393

DEL

 

CR1

Neurological disease [36, 37]

2q13

chr2:110517534–110698558

chr2:110095177–110276210

INV

Morbid CNV & Disease-related CNV

NPHP1, MALL, MTLN

Neurodevelopmental disorders [29, 30],Neurological disease [31]

3q29

chr3:198347865–198715835

chr3:195641035–195995576

DEL

Disease- related CNV

MUC20, MUC4, TNK2

Neurodevelopmental disorders [29, 30]

5p15.33

chr5:684792–685093

chr5:686991–779053

DEL

 

ZDHHC11B

Cancer [38]

6p21.32

chr6:32339743–32356931

chr6:32486765–32530206

DEL

 

HLA-DRB5

Immunological disease [39]

6q26

chr6:161865491–161959834

chr6:160612509–160612509

INS

 

LPA

Cardiovascular disease [40]

7q35

chr7:145,477,647–145477649

chr7:144197172–144295737

DEL

 

OR2A42, OR2A7, CTAGE8

Cancer [41]

8p23.1

chr8:750030–11722000

chr8:8022351–12234558

INV

Morbid CNV

DLGAP2, MYOM2, CLN8, ARHGEF, CSMD1, MCPH1, ANGPT2, PRR23D1, DEFB103B, DEFB103A, DEF104A, DEF105A, XKR6, SOX7, TNKS, PPP1R3B, PPAG1, CTSB, ANGPT2, AGPAT5, ERI1, MSRA, DEFA5, FDFT1, GATA4, MFHAS1, PRSS5

Developmental disorders [29, 30]

10q11.22

chr10:48671598–48719249

chr10:47780140–47870155

SDR

Disease-related CNV

GPRIN2

Neurological disease [42]

11p15.5

chr11:1076897–1087865

chr11:1017980–1017990

INS

 

MUC6

Neurological disease [43]

12p13.2

chr12:10315804–10315827

chr12:10429009–10444430

DEL

 

KLRC2

COVID-19 [44], Immunological disease [45]

16p11.2

chr16:30492288–30594258

chr16:30207700–30207750

INS

Disease- related CNV

NPIPB13, BOLA2B

Neurodevelopmental Disorders [29, 30, 46]

16p12.1–12.2

chr16:28619710–29091966

chr16:28339205–28811381

INV

Disease- related CNV

SULT1A1, SULT1A2, NPIPB8, NPIPB6 EIF3CL, NPIPB7, CLN3, IL27, EIF3C, NPIPB9

Neurodevelopmental disorders [29, 30], Neurological disease [31]

17p11.2

chr17:16716173–16767175

chr17:16813513–16821452

SDR

Disease-related CNV

LGALS9C

Neurodevelopmental disorders [29, 30]

17q12

chr17:37341285–37441106

chr17:36393230–36459266

SDR

Disease-related CNV

CCL3L1, CCL4L2, TBC1D3F

Neurodevelopmental disorders [29, 30]

19q13.2

chr19:42710594–42726422

chr19:39906200–39906250

INS

 

FCGBP

Reproductive system disease [47]

20p13

chr20:1629529–1629530

chr20:1580346–1613395

DEL

 

SIRPB1

Immunological disease [48]

22q11.23

chr22:24380000–24462473

chr22:23932712–24000827

SDR

Disease-related CNV

GSTT2, GSTT4, DDT

Neurodevelopmental disorders [29, 30], Neurological disease [31]

Xp11.22

chrX:50939534–50996879

chrX:51668108–51725222

INV

 

CENPVL1, CENPVL2

Neurodevelopmental disorders [49]

Xp22.33

chrX:1307333–1307498

chrX:1465426–1506104

DEL

 

P2RY8

Immunological disease [50]

Xq26.3

chrX:134047172–134104452

chrX:135721633–135795043

SDR

 

CT45A1, CT45A3, CT45A5,

Cancer [51]

Xq28

chrX:147946883–147987904

chrX:149681127–149722143

SDR

 

MAGEA11

Cancer [52]

  1. Morbid CNV refers to Ref. [29, 30]
  2. Disease-related CNV refers to the Ref. [31]